Abstract

Regulatory error is an issue that has come to the fore following the withdrawal of rofecoxib (Vioxx; Merck) a year ago. Here, we provide a theoretical discussion of the factors that could influence regulatory error, drawing on the Vioxx episode in particular as a possible example of error, and consider the implications for future regulatory policy.

Author affiliations

1. Daniel Carpenter is in the Department of Government, 1737 Cambridge St, CGIS N405, Harvard University, Cambridge, Massachusetts 02138, USA.
   Email: dcarpenter@latte.harvard.edu
2. Michael M. Ting is in the Department of Political Science, International Affairs Building, Floor 7, 420 West 118th Street, New York, New York 10027, USA.
   Email: mmt2033@columbia.edu

Published online 23 September 2005

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.